

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### MTA Adalimumab and dexamethasone for treating non-infectious uveitis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

The potential issues raised during scoping were not considered specific equalities issues.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

The company submission states that the equality impact of recommendations for those patients for whom vision may be reduced or lost in one eye already may need to be assessed, as this group is at risk of becoming sight disabled. The committee discussed the impact of uveitis that affects one eye (unilateral disease) and uveitis that affects both eyes (bilateral disease) and agreed that the risk of permanent blindness was higher when both eyes were affected. Both groups were considered when making recommendations.
---

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No additional equalities issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No- the preliminary recommendations do not make it more difficult in practice for a specific group to access the technology

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

N/A the committee did not identify any specific equalities issues.

**Approved by Associate Director (name):** ...Frances Sutcliffe.....

**Date:** 03/03/2017

## Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

The committee noted comments suggesting that, without positive NICE guidance, there may be equity issues from variation in access to adalimumab and dexamethasone within the UK. The committee agreed that this does not represent a potential equality issue.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the recommendations do not make it more difficult in practice for a specific group to access the technology

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

N/A the committee did not identify any specific equalities issues.

**Approved by Associate Director (name):** Frances Sutcliffe...

**Date:** 18/05/2017